BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22985957)

  • 1. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
    Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors.
    Li CY; Li QS; Yan L; Sun XG; Wei R; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Jun; 20(12):3746-55. PubMed ID: 22583669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase.
    Yang YS; Li QS; Sun S; Zhang YB; Wang XL; Zhang F; Tang JF; Zhu HL
    Bioorg Med Chem; 2012 Oct; 20(20):6048-58. PubMed ID: 22985962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF(V⁶⁰⁰E) inhibitors.
    Zhao MY; Yin Y; Yu XW; Sangani CB; Wang SF; Lu AM; Yang LF; Lv PC; Jiang MG; Zhu HL
    Bioorg Med Chem; 2015 Jan; 23(1):46-54. PubMed ID: 25496804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents.
    Wang HH; Qiu KM; Cui HE; Yang YS; Yin-Luo ; Xing M; Qiu XY; Bai LF; Zhu HL
    Bioorg Med Chem; 2013 Jan; 21(2):448-55. PubMed ID: 23245802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
    Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
    Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAF(V600E) inhibitors.
    Dong JJ; Li QS; Wang SF; Li CY; Zhao X; Qiu HY; Zhao MY; Zhu HL
    Org Biomol Chem; 2013 Oct; 11(37):6328-37. PubMed ID: 23942809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents.
    Li QS; Lv XH; Zhang YB; Dong JJ; Zhou WP; Yang Y; Zhu HL
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6596-601. PubMed ID: 23025996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.
    Yang W; Hu Y; Yang YS; Zhang F; Zhang YB; Wang XL; Tang JF; Zhong WQ; Zhu HL
    Bioorg Med Chem; 2013 Mar; 21(5):1050-63. PubMed ID: 23391364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
    Kim MH; Kim M; Yu H; Kim H; Yoo KH; Sim T; Hah JM
    Bioorg Med Chem; 2011 Mar; 19(6):1915-23. PubMed ID: 21353571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
    Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification, biological evaluation and 3D QSAR studies of novel 2-(1,3-diaryl- 4,5-dihydro-1H-pyrazol-5-yl)phenol derivatives as inhibitors of B-Raf kinase.
    Yang YS; Zhang F; Tang DJ; Yang YH; Zhu HL
    PLoS One; 2014; 9(5):e95702. PubMed ID: 24827980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents.
    Lv PC; Li HQ; Sun J; Zhou Y; Zhu HL
    Bioorg Med Chem; 2010 Jul; 18(13):4606-14. PubMed ID: 20627597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.
    Li X; Lu X; Xing M; Yang XH; Zhao TT; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3589-93. PubMed ID: 22572580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors.
    Li QS; Li CY; Lu X; Zhang H; Zhu HL
    Eur J Med Chem; 2012 Apr; 50():288-95. PubMed ID: 22361686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAF
    Li HL; Su MM; Xu YJ; Xu C; Yang YS; Zhu HL
    Eur J Med Chem; 2018 Jul; 155():725-735. PubMed ID: 29940463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.
    Li X; Liu JL; Yang XH; Lu X; Zhao TT; Gong HB; Zhu HL
    Bioorg Med Chem; 2012 Jul; 20(14):4430-6. PubMed ID: 22705022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies.
    Choi WK; El-Gamal MI; Choi HS; Baek D; Oh CH
    Eur J Med Chem; 2011 Dec; 46(12):5754-62. PubMed ID: 22014559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
    Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.
    Duffey MO; Adams R; Blackburn C; Chau RW; Chen S; Galvin KM; Garcia K; Gould AE; Greenspan PD; Harrison S; Huang SC; Kim MS; Kulkarni B; Langston S; Liu JX; Ma LT; Menon S; Nagayoshi M; Rowland RS; Vos TJ; Xu T; Yang JJ; Yu S; Zhang Q
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4800-4. PubMed ID: 20634068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.